Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 22 of 25, showing 5 Applications out of 121 total, starting on record 106, ending on 110

# Protocol No Study Title Investigator(s) & Site(s)

106.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
View

107.

ECCT/15/11/05   FALCI Study
    A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria.   
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
1. KEMRI Center for Respiratory Diseases Research (Siaya county)
2. KEMRI Walter Reed Kombewa (Kisumu county)
3. KEMRI Kisumu (Kisumu county)
 
View

108.

ECCT/09/06/02  
    A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy   plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual   Transmission of HIV-1 In Serodiscordant Couples   
Principal Investigator(s)
1. Lisa Ann Mills
Site(s) in Kenya
Kisumu, Kenya
 
View

109.

ECCT/23/10/01   CROSSWALK Chronic (C)
    A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) IN SICKLE CELL DISEASE (SCD) (CROSSWALK-c)   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Doreen Terry Karimi
Site(s) in Kenya
1. Gertrudes Childrens Hospital (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

110.

ECCT/22/12/03   heredERA
    A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO + TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
2. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View